Bayer AG and Loxo Oncology Inc has entered into a global collaboration for the development and commercialization of larotrectinib (LOXO-101) and LOXO-195. Both compounds are being investigated in global studies for the treatment of patients with cancers harboring tropomyosin receptor kinase (TRK) gene fusions, which are genetic alterations across a wide range of tumors resulting in uncontrolled TRK signaling and tumor growth.
Bayer and Loxo Oncology will jointly develop the two products, larotrectinib and LOXO-195, and share development costs on a 50:50 basis. Bayer will lead ex-US regulatory activities, and worldwide commercial activities. Loxo Oncology will remain responsible for the filing in the U.S.
Larotrectinib (LOXO-101)
Larotrectinib (LOXO-101) is a potent, oral and selective investigational new drug in clinical development for the treatment of patients across a wide range of cancers that harbor abnormalities involving the TRKs. Growing research suggests that the neurotropic tropomyosin receptor kinase (NTRK) genes, which encode for TRKs, can become abnormally fused to other genes, resulting in growth signals that can lead to cancer in many sites of the body.
No comments:
Post a Comment